Literature DB >> 12782057

Vaccine research efforts for filoviruses.

Mary Kate Hart1.   

Abstract

Ebola and Marburg viruses belong to the family Filoviridae, and cause acute, frequently fatal, haemorrhagic fever in humans and non-human primates. No vaccines are available for human use. This review describes the status of research efforts to develop vaccines for these viruses and to identify the immune mechanisms of protection. The vaccine approaches discussed include DNA-based vaccines, and subunit vaccines vectored by adenovirus, alphavirus replicons, and vaccinia virus.

Entities:  

Mesh：

Substances：

Year:  2003        PMID： 12782057     DOI： 10.1016/s0020-7519(03)00064-x

Source DB:  PubMed          Journal:  Int J Parasitol        ISSN： 0020-7519            Impact factor:   3.981


  21 in total

1.  Ebola virus VP24 proteins inhibit the interaction of NPI-1 subfamily karyopherin alpha proteins with activated STAT1.

Authors:  St Patrick Reid; Charalampos Valmas; Osvaldo Martinez; Freddy Mauricio Sanchez; Christopher F Basler
Journal:  J Virol       Date:  2007-10-10       Impact factor: 5.103

Review 2.  Advances in virus-like particle vaccines for filoviruses.

Authors:  Kelly L Warfield; M Javad Aman
Journal:  J Infect Dis       Date:  2011-11       Impact factor: 5.226

3.  Development of a cAdVax-based bivalent ebola virus vaccine that induces immune responses against both the Sudan and Zaire species of Ebola virus.

Authors:  Danher Wang; Nicholas U Raja; Charles M Trubey; Laure Y Juompan; Min Luo; Jan Woraratanadharm; Stephen B Deitz; Hong Yu; Benjamin M Swain; Kevin M Moore; William D Pratt; Mary Kate Hart; John Y Dong
Journal:  J Virol       Date:  2006-03       Impact factor: 5.103

4.  A DNA vaccine for Ebola virus is safe and immunogenic in a phase I clinical trial.

Authors:  Julie E Martin; Nancy J Sullivan; Mary E Enama; Ingelise J Gordon; Mario Roederer; Richard A Koup; Robert T Bailer; Bimal K Chakrabarti; Michael A Bailey; Phillip L Gomez; Charla A Andrews; Zoe Moodie; Lin Gu; Judith A Stein; Gary J Nabel; Barney S Graham
Journal:  Clin Vaccine Immunol       Date:  2006-09-20

5.  Protection against lethal challenge by Ebola virus-like particles produced in insect cells.

Authors:  Yuliang Sun; Ricardo Carrion; Ling Ye; Zhiyuan Wen; Young-Tae Ro; Kathleen Brasky; Anysha E Ticer; E Ellen Schwegler; Jean L Patterson; Richard W Compans; Chinglai Yang
Journal:  Virology       Date:  2008-11-04       Impact factor: 3.616

6.  Replication-deficient ebolavirus as a vaccine candidate.

Authors:  Peter Halfmann; Hideki Ebihara; Andrea Marzi; Yasuko Hatta; Shinji Watanabe; M Suresh; Gabriele Neumann; Heinz Feldmann; Yoshihiro Kawaoka
Journal:  J Virol       Date:  2009-02-11       Impact factor: 5.103

7.  Evaluation of Different Strategies for Post-Exposure Treatment of Ebola Virus Infection in Rodents.

Authors:  Jason S Richardson; Gary Wong; Stéphane Pillet; Samantha Schindle; Jane Ennis; Jeffrey Turner; James E Strong; Gary P Kobinger
Journal:  J Bioterror Biodef       Date:  2011-10-20

8.  Virus nomenclature below the species level: a standardized nomenclature for laboratory animal-adapted strains and variants of viruses assigned to the family Filoviridae.

Authors:  Jens H Kuhn; Yiming Bao; Sina Bavari; Stephan Becker; Steven Bradfute; J Rodney Brister; Alexander A Bukreyev; Yíngyún Caì; Kartik Chandran; Robert A Davey; Olga Dolnik; John M Dye; Sven Enterlein; Jean-Paul Gonzalez; Pierre Formenty; Alexander N Freiberg; Lisa E Hensley; Anna N Honko; Georgy M Ignatyev; Peter B Jahrling; Karl M Johnson; Hans-Dieter Klenk; Gary Kobinger; Matthew G Lackemeyer; Eric M Leroy; Mark S Lever; Loreen L Lofts; Elke Mühlberger; Sergey V Netesov; Gene G Olinger; Gustavo Palacios; Jean L Patterson; Janusz T Paweska; Louise Pitt; Sheli R Radoshitzky; Elena I Ryabchikova; Erica Ollmann Saphire; Aleksandr M Shestopalov; Sophie J Smither; Nancy J Sullivan; Robert Swanepoel; Ayato Takada; Jonathan S Towner; Guido van der Groen; Viktor E Volchkov; Victoria Wahl-Jensen; Travis K Warren; Kelly L Warfield; Manfred Weidmann; Stuart T Nichol
Journal:  Arch Virol       Date:  2013-01-29       Impact factor: 2.574

9.  Chemical modifications of antisense morpholino oligomers enhance their efficacy against Ebola virus infection.

Authors:  Dana L Swenson; Kelly L Warfield; Travis K Warren; Candace Lovejoy; Jed N Hassinger; Gordon Ruthel; Robert E Blouch; Hong M Moulton; Dwight D Weller; Patrick L Iversen; Sina Bavari
Journal:  Antimicrob Agents Chemother       Date:  2009-02-17       Impact factor: 5.191

10.  Development and characterization of a mouse model for Marburg hemorrhagic fever.

Authors:  Kelly L Warfield; Steven B Bradfute; Jay Wells; Loreen Lofts; Meagan T Cooper; D Anthony Alves; Daniel K Reed; Sean A VanTongeren; Christine A Mech; Sina Bavari
Journal:  J Virol       Date:  2009-04-15       Impact factor: 5.103
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.